HRMY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Harmony Biosciences Holdings Inc (HRMY) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has potential upside in the short term, the significant risks related to patent disputes, declining financial performance, and mixed analyst ratings suggest a cautious approach. Holding the stock or waiting for further clarity on catalysts is recommended.
The technical indicators are neutral to slightly positive. The MACD is above zero and positively contracting, indicating mild bullish momentum. RSI is at 73.887, suggesting the stock is nearing overbought territory. Moving averages are converging, and the stock is trading near its resistance level of 29.602, with a pivot at 28.582.
Hedge funds are significantly increasing their positions in HRMY, with a 18208.08% increase in buying over the last quarter. Additionally, the company has reached settlements with generic filers, potentially delaying generic competition until September 2029.
The company faces substantial patent risks, with potential generic competition as early as 2026 if patents are lost. Analysts have downgraded the stock and reduced price targets, citing risks to the Wakix franchise. Financial performance in Q4 2025 showed a significant decline in net income (-54.55% YoY) and EPS (-54.12% YoY), despite revenue growth.
In Q4 2025, revenue increased by 21.12% YoY to $243.78M. However, net income dropped significantly by 54.55% YoY to $22.49M, and EPS fell by 54.12% YoY to 0.39. Gross margin also declined slightly to 71.88%, down 1.49% YoY.
Analysts are largely neutral to bearish on HRMY. UBS, Deutsche Bank, and Truist have downgraded the stock to Hold or Neutral, citing patent risks and limited near-term catalysts. Recent price target reductions range from $28 to $36, reflecting cautious sentiment.
